Alzheimer's disease drug development pipeline: 2019

INTRODUCTION: Alzheimer's disease (AD) has few available treatments, and there is a high rate of failure in AD drug development programs. Study of the AD drug development pipeline can provide insight into the evolution of drug development and how best to optimize development practices. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, Jeffrey, Lee, Garam, Ritter, Aaron, Sabbagh, Marwan, Zhong, Kate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617248/
https://www.ncbi.nlm.nih.gov/pubmed/31334330
http://dx.doi.org/10.1016/j.trci.2019.05.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617248/
https://www.ncbi.nlm.nih.gov/pubmed/31334330
http://dx.doi.org/10.1016/j.trci.2019.05.008

Ejemplares similares